Cryo-EM of ATP-driven dynamics and itraconazole binding of the fungal drug efflux ABC pump Candida glabrata Cdr1

This study utilizes high-resolution cryo-EM and 3D variability analysis to reveal the ATP-driven conformational dynamics and itraconazole binding mechanism of the fungal drug efflux pump Cdr1, providing a structural framework for understanding azole resistance and the chemo-mechanical cycle of ABC transporters.

The Gist

The Big Picture: The Fungal "Bouncer"

Imagine a yeast cell (specifically Candida glabrata) as a high-security nightclub. The club has a bouncer at the door whose job is to keep out troublemakers. In this case, the "troublemakers" are antifungal drugs (like itraconazole) that try to kill the yeast.

The bouncer is a protein called Cdr1. It's an "efflux pump," which is a fancy way of saying it's a machine that grabs drugs from inside the cell and throws them back out before they can do any damage. This is why many fungal infections are so hard to treat; the yeast just pumps the medicine out faster than it can work.

Until now, scientists knew this bouncer existed, but they didn't have a clear, moving picture of how it actually works. They had static photos, but they needed a movie to see the mechanics. This paper provides that movie.

The Breakthrough: A High-Speed Movie in 4K

The researchers used a powerful microscope called Cryo-EM (Cryo-Electron Microscopy) to take thousands of snapshots of the Cdr1 bouncer. By combining these snapshots, they created a high-resolution, 3D "movie" of the protein in action.

They captured the bouncer in four different "poses":

1. The Resting Pose: Empty and waiting.
2. The Loading Pose: Holding the drug (itraconazole) inside.
3. The Power-Up Pose: Charged with energy (ATP).
4. The Ejection Pose: After using the energy to kick the drug out.

How the Machine Works: The "Piston" and the "Squeeze"

The most exciting discovery is the step-by-step mechanism of how the pump moves. The authors describe it using two main movements:

1. The Piston Pull (The Trigger)
Imagine the bouncer has a spring-loaded lever inside its chest. When the protein grabs a packet of energy (ATP), it hydrolyzes it (breaks it down). This causes a specific part of the protein, called the C-helix, to snap back like a piston pulling a trigger.

• The Analogy: Think of a piston in a car engine. When the spark happens, the piston pulls back. In this protein, that single "pull" is the very first thing that happens. It's the signal that says, "Okay, we are going to move now!"

2. The Squeeze-and-Push (The Ejection)
Once that piston pulls back, it sends a ripple effect through the rest of the machine.

• The Squeeze: The walls of the tunnel where the drug sits (the Transmembrane Helices) start to twist and bend. Specifically, one wall (TMH-2) partially unravels to make room for the drug to sit comfortably.
• The Push: Then, the whole machine rotates and squeezes. It's like a hand squeezing a tube of toothpaste. The tunnel narrows, and the drug is physically forced out of the cell and into the outside world.

The Drug's Shape-Shifting Trick

The researchers also looked closely at how the drug itraconazole fits into the pump.

• The Analogy: Imagine trying to fit a large, awkward suitcase into a small car trunk. Usually, you'd have to force it. But here, the suitcase (the drug) is flexible. It folds itself into an "n-shape" (like a bent knee) to perfectly tuck itself into the bouncer's grip.
• The protein is also flexible; it slightly deforms its own shape to hug the drug. This explains why the pump can handle many different types of drugs—it's a "chameleon" pump that can adapt its shape to grab whatever is thrown at it.

The Secret Anchor: Ergosterol

The study also found that the pump is glued to the cell membrane by ergosterol molecules (a type of fat found in yeast).

• The Analogy: Think of the pump as a ship, and the ergosterol molecules as the anchors or ballast. They hold the ship steady in the rough ocean of the cell membrane. Without these anchors, the pump might wobble too much to work efficiently. The researchers found that the pump holds onto these anchors very tightly, suggesting they are crucial for the machine's stability.

Why This Matters

This paper is a game-changer for two reasons:

1. Understanding Resistance: It explains exactly how the fungus resists drugs. It's not magic; it's a mechanical process involving a piston, a squeeze, and a push.
2. Designing Better Drugs: Now that we have the "blueprint" and the "movie" of the bouncer, scientists can design new drugs that either:
   • Jam the piston so it can't pull back.
   • Block the "squeeze" so the drug can't be ejected.
   • Trick the pump into thinking a harmless molecule is a drug, wasting its energy.

In summary: This research took a microscopic, invisible machine and turned it into a clear, 3D animation. We now know that the fungal bouncer works by pulling a piston, folding the drug into a specific shape, and squeezing it out of the cell. With this knowledge, we are one step closer to building a key that can lock the door and stop the infection.

Technical Summary

1. Problem Statement

• Clinical Context: Fungal infections, particularly those caused by Candida species (e.g., C. glabrata), are a major global health threat. A primary mechanism of resistance to azole antifungals (the most widely used class of antifungals) is the overexpression of the ATP-binding cassette (ABC) transporter Cdr1.
• Knowledge Gap: While the functional role of Cdr1 in expelling drugs is well-established, the structural basis for its ATP-driven transport cycle and its interaction with substrates like itraconazole has remained elusive. Previous structural attempts were hindered by difficulties in preserving the functional integrity of these proteins outside their native membrane and by low-resolution data.
• Specific Questions: How does ATP hydrolysis drive the conformational changes required for drug extrusion? How does the drug-binding site (DBS) accommodate diverse substrates? What is the specific role of the non-catalytic nucleotide-binding site (ncNBS) versus the catalytic site (cNBS)?

2. Methodology

The authors employed a multidisciplinary approach combining biochemistry, functional assays, and advanced cryo-electron microscopy (cryo-EM):

• Protein Expression and Purification:
  • CgCdr1 was overexpressed in a Saccharomyces cerevisiae strain (AD1-8u-) engineered to be hypersensitive to drugs due to the deletion of endogenous ABC transporters.
  • The protein was extracted from the membrane fraction (C20K) using a specialized detergent mixture (trans-PCC-α-M and dicarboxylate oside 9b) to maintain functional integrity.
  • Purification was achieved via Ni-NTA affinity chromatography and size-exclusion chromatography.
• Functional Characterization:
  • ATPase Activity: Measured to confirm functionality. The purified protein showed high ATPase activity (3–5 µmol·min⁻¹·mg⁻¹) sensitive to PDR pump inhibitors (oligomycin, FK506).
  • Drug Binding: Intrinsic fluorescence quenching assays were used to determine binding affinities ($K_D$) for ATP and itraconazole.
  • Lipid Analysis: Mass spectrometry (GC-MS/MS and UHPLC-MS/MS) quantified endogenous lipids (ergosterol, PE, PC) associated with the purified protein.
• Cryo-EM Data Collection and Processing:
  • Samples were prepared in four states: Apo (ligand-free), ATP-Mg²⁺ + Vanadate (mimicking the post-hydrolysis ADP·Pi state), ATP-Mg²⁺ + Vanadate + Itraconazole, and ATP-Mg²⁺ alone.
  • Data was collected on Titan Krios microscopes (Stockholm and Grenoble).
  • Advanced Analysis: The study utilized 3D Variability Analysis (3DVA) in CryoSPARC to capture continuous conformational transitions rather than static snapshots. This allowed for the reconstruction of a "movie" of the transport cycle.
  • Refinement: Models were built using phenix.varref and validated against high-resolution density maps.

3. Key Contributions and Results

A. High-Resolution Structural Snapshots

The authors resolved four high-resolution structures of CgCdr1:

1. Apo State: Inward-facing, open conformation.
2. Closed State ([s0|ncATP|cADP-Vi-Mg]): Nucleotide-bound, mimicking the transition state before phosphate release.
3. Open State ([s0|ncATP|cADP-Mg]): Post-hydrolysis, inward-facing open conformation.
4. Drug-Bound State ([sITC|ncATP|cADP-Mg]): Itraconazole bound in the inward-facing conformation.

B. Mechanism of ATP-Driven Dynamics (The "Motion Cascade")

Using 3DVA, the study revealed a step-by-step mechanism triggered by ATP hydrolysis at the catalytic site (cNBS):

1. Piston-like Retraction: The earliest detectable change is a ~4 Å rigid retraction of the C-helix (H-8) in NBD-1 away from the $\gamma$-phosphate/vanadate. This acts as a piston.
2. Domain Rotation: This retraction triggers a ~10° rotation of the entire NBD-1 domain, centered on the $\beta$-sheet.
3. Transmembrane Propagation: The rotation is transmitted to the Transmembrane Domain (TMD-1), causing a global opening of the transporter.
4. Asymmetric Motion: TMD-1 (containing TMH-1, -2, -3, -6) shows large displacements (3–5 Å), while TMD-2 acts as a relatively stable pivot.
5. Substrate Extrusion ("Squeeze-and-Push"): A secondary analysis (Component C1) revealed a "squeeze-and-push" motion where TMH-2 and TMH-5 collapse toward the center of the drug-binding site (DBS) and move upward, likely forcing the substrate out through an extracellular exit valve.

C. The Role of Nucleotide Binding Sites

• ncNBS (Non-catalytic): ATP binds with very high affinity ($K_D \approx 0.3 \mu M$) and remains bound throughout the entire transport cycle, acting as a structural cofactor and a pivot for domain rotation. It does not hydrolyze.
• cNBS (Catalytic): Binds and hydrolyzes ATP. The release of the inorganic phosphate (or vanadate mimic) triggers the conformational change.

D. Itraconazole Binding and Adaptation

• Conformation: Itraconazole binds in an n-shaped conformation within the DBS, adapting its shape to fit the pocket.
• Binding Mode: It interacts primarily via hydrophobic and Van der Waals forces with residues from TMH-1, -2, -5, -8, and -11. A specific halogen bond forms between the drug's dichlorophenyl group and residue N1345.
• Induced Fit: Binding induces local deformations, specifically the unwinding of two helical turns in TMH-2 (residues 559–565), creating space for the drug. This confirms the DBS is flexible and adaptable to diverse substrates.
• Stabilization: Itraconazole binding stabilizes the inward-facing conformation even after ATP hydrolysis, suggesting it "traps" the pump in a state ready for the next cycle.

E. Ergosterol Interaction

• The structures revealed 10 tightly bound ergosterol molecules per Cdr1 monomer.
• These lipids are asymmetrically distributed, primarily stabilizing TMD-2. They likely act as structural anchors, reinforcing the rigidity of the non-catalytic side of the pump, which is crucial for the mechanics of the transport cycle.

4. Significance

• Mechanistic Insight: This study provides the first experimentally verified, detailed description of the chemo-mechanical cycle of a fungal PDR transporter. It resolves the long-standing question of how ATP hydrolysis is coupled to substrate extrusion in these asymmetric pumps.
• Dynamic Framework: The use of 3DVA to capture transient states (like the piston-like C-helix retraction) offers a new paradigm for understanding ABC transporter dynamics, moving beyond static "open/closed" models to a continuous motion model.
• Drug Resistance & Design: By visualizing how itraconazole binds and how the pump adapts, the study identifies specific residues (e.g., in TMH-2 and TMH-8) critical for drug accommodation. This provides a structural basis for designing next-generation antifungals that can either bypass the efflux mechanism or inhibit the pump's conformational cycle.
• General Applicability: The findings regarding the non-catalytic ATP binding and the specific motion of the C-helix likely apply to other fungal PDR transporters (like Pdr5) and potentially other members of the ABC superfamily, offering a conserved mechanistic framework.

In summary, this paper bridges the gap between biochemical function and structural biology for Cdr1, revealing a sophisticated, multi-step mechanical cycle driven by a rigid C-helix retraction and facilitated by a flexible, ergosterol-stabilized drug-binding pocket.